| Literature DB >> 35208961 |
Mohamed A Ashour1,2, Waseem Fatima3, Mohd Imran4, Mohammed M Ghoneim5, Sultan Alshehri6, Faiyaz Shakeel6.
Abstract
Acacia seyal is an important source of gum Arabic. The availability, traditional, medicinal, pharmaceutical, nutritional, and cosmetic applications of gum acacia have pronounced its high economic value and attracted global attention. In addition to summarizing the inventions/patents applications related to gum A. seyal, the present review highlights recent updates regarding its phytoconstituents. Traditional, cosmetic, pharmaceutical, and medicinal uses with the possible mechanism of actions have been also reviewed. The patent search revealed the identification of 30 patents/patent applications of A. seyal. The first patent related to A. seyal was published in 1892, which was related to its use in the prophylaxis/treatment of kidney and bladder affections. The use of A. seyal to treat cancer and osteoporosis has also been patented. Some inventions provided compositions and formulations containing A. seyal or its ingredients for pharmaceutical and medical applications. The inventions related to agricultural applications, food industry, cosmetics, quality control of gum Arabic, and isolation of some chemical constituents (L-rhamnose and arabinose) from A. seyal have also been summarized. The identification of only 30 patents/patent applications from 1892 to 15 November 2021 indicates a steadily growing interest and encourages developing more inventions related to A. seyal. The authors recommend exploring these opportunities for the benefit of society.Entities:
Keywords: Acacia seyal; Arabic gum; gum Arabic; invention; patent
Mesh:
Substances:
Year: 2022 PMID: 35208961 PMCID: PMC8874428 DOI: 10.3390/molecules27041171
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1The main phytoconstituents of A. seyal.
Figure 2Part of the fundamental chain of gum Arabic shows 1-3-linked β-D-galactopyranosyl residues and its main branches. (Gal) β-D-galactopyranose, (Ara) α-l-arabinofuranose, (Rha) α-l-rhamnopyranose, (GlcA) β-D-glucuronic acid, and (mGlcA) 4-O-methyl-β-D-glucuronic acid.
Figure 3The main monosaccharide residues in gum Arabic: (A) β-D-galactopyranose, (B) α-l-arabinofuranose, (C) α-l-rhamnopyranose, (D) β-D-glucuronic acid, and (E) 4-O-methyl-β-D-glucuronic acid.
Analytical data (percentage values) of precepitated fractionsn of Acacia seyal gum Arabic compared with its entire substance according to Li et al. 2020 [25].
| Fraction | AY60 | AY 80 | AYS | AY (Entire Substance) |
|---|---|---|---|---|
| Weight percentage (%) | 44 | 39 | 2.4 | 100 |
| Average molecular weight | 924,900 Da | ND | ND | ND |
| % moisture content | 12.67 ± 0.04 | 13.59 ± 0.21 | ND | 14.41 ± 0.11 |
| % Ash content | 4.44 ± 0.01 | 4.51 ± 0.02 | ND | 3.50 ± 0.02 |
| % total protein content | 0.14 ± 0.01 | 0.13 ± 0.06 | 0.45 ± 0.02 | 0.32 ± 0.02 |
| % neutral sugar content | 61.24 ± 3.44 | 63.82 ± 2.76 | 67.82± 1.62 | 60.90 ±2.13 |
| % uronic acid content | 15.26 ± 0.25 | 16.17 ± 0.19 | 1.83 ± 0.07 | 17.43 ± 0.62 |
| the total molar percentage (mol%) of rhamnose | 2.13 | 2.24 | 2.28 | 3.09 |
| mol% of arabinose | 43.54 | 44.80 | 40.13 | 47.29 |
| mol% of galactose | 39.38 | 37.22 | 49.61 | 33.00 |
| mol% of galacturonic acid | 14.95 | 15.74 | 1.54 | 16.62 |
ND: not determined.
Traditional uses of A. seyal in some African countries.
| Country | Use | Part | Ref. |
|---|---|---|---|
| Kenya | Pneumonia | Bark, stem, trunk, twig | [ |
| Kenya | Malaria | Roots | [ |
| Kenya | Joint pain | Bark, stems, leaves | [ |
| Sudan | Bleeding, leprosy | Bark, leaves | [ |
| Sudan | Arthritis, rheumatisms, rheumatoid fever | Wood | [ |
| Ethiopia | Intestinal parasites | Roots, leaves | [ |
| Ethiopia | Chest pain | Roots | [ |
| Uganda | Diarrhea, Viral skin necrosis nodules | Roots, bark, leaves | [ |
| Djibouti | Dysentery | Bark, roots | [ |
| Algeria, Egypt, Morocco | Infected wounds, fever, dysmenorrhea, eye infections, stomach ulcers, rheumatisms | Seed | [ |
| Algeria, Egypt, Morocco | Rheumatisms, respiratory tract infection, gastric ulcer | Gum | [ |
The pharmacological relevance of gum Arabic.
| Pharmacological Activity | Possible Mechanism of Action | Refs. |
|---|---|---|
| Antiulcerative effect | It provides an antisecretory and cytoprotective effect on GIT. | [ |
| Wound healing effect | Inhibits periodontic bacterial growth and early deposition of plaque. | [ |
| Protective effect on the reproductive system | GA protects the ovary from oxidative stress damage in mice fed with a high-fat diet and increases sperm and semen qualities in the diabetic rat. | [ |
| Hepatoprotective effect | GA decreases serum bilirubin level and other liver function markers (ALT, AST) and decreases symptoms of liver damage by restoring the architecture of liver tissue. | [ |
| Activity against adenine-induced renal failure | GA mitigates the adenine-induced inflammation and generation of free radicals, resulting in reduced concentrations of plasma urea and creatinine. | [ |
| Activity against Hg-induced nephrotoxicity | It prevented Hg-induced degenerative changes of kidney tissues. | [ |
| Activity on renal function | It has a significant reduction in blood urea and creatinine concentrations in diabetic nephropathy patients. | [ |
| Improvement of chronic renal failure | GA can activate colonic bacteria to produce ureases that hydrolyze urea to NH3 and CO2, NH3 excreted in feces through incorporation into bacterial protein. GA increases serum level of butyrate, which prevents the generation of pro-fibrotic cytokine TGF-B1 that contributes to renal fibroblast. | [ |
| Activity against doxorubicin induced-cardiotoxicity | It has significant reduction effects on serum creatine kinase and cardiac lipid peroxides. | [ |
| Health benefits on the cardiovascular system | GA showed a significant decrease in systolic and diastolic blood pressure. It has a hypocholesterolemic effect, decreasing low-density lipoproteins (LDL) and very-low-density lipoproteins (VLDL). | [ |
| Antioxidant activity | GA increases the activity of superoxide dismutase, catalase, and glutathione peroxidase in the liver of diabetic rats by either directly scavenging free radicals or reactive oxygen metabolites or via increasing the synthesis of antioxidant biomolecules. | [ |
| Anti-inflammatory effects | GA fibers decreased inflammatory markers and disease severity scores among rheumatoid arthritis patients. | [ |
| Supportive treatment of gout | GA reduces in a dose-dependent manner the serum levels of uric acid, urea, creatinine, and erythrocyte sedimentation rate level while increasing the hemoglobin and packed cell volume. | [ |
| Effects on fat metabolism and obesity | GA lowers sugar and fat absorption and lowers the caloric density of the diet. It improves the fat utilization in adipose tissues, alternating the expression of mRNA levels of genes involved in lipid metabolism. It has a downregulation effect on 11β-hydroxysteroid dehydrogenase type 1 and increases the viscosity of gastrointestinal contents, thus delaying the evacuation of GIT and contributing to a feeling of satiety. GA influences the gut hormones and enzymes that regulate food intake, satiety, and pancreatic functions. It has metabolic energy dilution, bulking, and satiety effects and aids fermentation to produce short-chain fatty acids and increase GLP-1 and PYY. GA diminishes intestinal SGLT1 expression and activity and glucose-actuated overweight. | [ |
| Antihypercholesterolimic effect | GA decreases plasma triglyceride, total cholesterol, low-density lipoprotein (LDL), and very-low-density lipoprotein. GA disrupts the enterohepatic circulation of bile acids, leading to increased bile acid excretion. | [ |
| Antidiabetic effect | The gel-forming and viscosity of GA inhibit intestinal absorption of macronutrients, enhancement of insulin sensitivity, and modification of certain gut hormones secretion | [ |
| Immunomodulatory effects | GA increased the percentage of CD11c+CD40+, CD11c+MHCII+, CD11c+CD86+, and CD54− expressing DCs; in addition, it stimulated the production of IL-6, IL-10, IL12p70, and TNF-α in a p38- and/or extracellular signal-regulated kinases (ERK)-dependent manner. | [ |
| Antibacterial activity | Due to poly-phenolic (tannins) and saponin contents, GA has antibacterial activities against pathogenic bacteria. GA can also stimulate the growth of probiotic bacteria that protect the body against pathogenic bacteria. | [ |
| Anti-sickle-cell anemia | GA increases fetal hemoglobin (HbF) level, mean corpuscular volume, and hematocrit level. | [ |
| Antimalaria effect | GA metabolites (short-chain fatty acids) increase the level of HbF, which is known to hamper the intra-erythrocytic growth of Plasmodium parasites. | [ |
| Anticarcinogenic effect | GA modifies cancer-related genes’ mRNA expression. Antioxidant amino acids contents of GA have radical scavenging activities. GA is involved as a nanomaterial for the preparation of anticancer nano-pharmaceuticals, e.g., gold nanoparticles and selenium nanoparticles. GA decreased the colonic mRNA levels of the angiogenetic factors and diminished ss-catenin expression. | [ |
| Dermatological activity | It is used as an antiallergic, smoothing, protective, binding, and/or stabilizing agent in cosmetic preparations. It has an anti-inflammatory effect against Kwashiorkor skin lesions and decreases skin inflammation (redness). | [ |
| Water and electrolyte up-taking | GA increases water and electrolyte movement from the intestinal lumen to the bloodstream. | [ |
| Gut probiotic effect | GA increases the growth of colonic beneficial strains of Lactobacillus and Bifidobacterium. GA selectively nourishes gut microbiota and aid to produces short-chain fatty acids, especially butyrate, and inhibits pathogenic organisms, e.g., the Clostridium histolyticum group, that are commonly associated with gut dysbiosis. | [ |
| Dentistry applications | It upgrades dental re-mineralization and has some antimicrobial effects. It showed antiplaque on the gums and teeth and anti-gingivitis actions. | [ |
Importance of gum Arabic in food and pharmaceutical industries.
| Industrial Relevance | Its Role | Refs. |
|---|---|---|
| Adjustment of medication delivery | GA microspheres facilitate absorption and expand the bioavailability of drugs. | [ |
| Nanotechnology | GA is a renewable, biocompatible, biodegradable, and non-harmful nanomaterial. | [ |
| Additive in Food and pharmaceutical industry | GA has many applications as an emulsifier, stabilizer, thickener, processing aid, firming agent, texturizer, adhesive, plasticizer, and formulation aid. | [ |
| Confectionery industry | GA prevents sugar crystallization, modifies texture, emulsifies, acts as a binder, and keeps fatty components evenly distributed. | [ |
| Baking products | GA has comparatively low water absorption and favorable adhesive properties. It imparts stability in bun glaze with free-flowing and adhesive characteristics. | [ |
| high-quality emulsifying conjugate | [ |
Summary of the patents/patent applications related to A. seyal.
| S. No. | Patent/Patent Application Number | International Patent Classification | Status on 15 November 2021 | Summary |
|---|---|---|---|---|
| 1 | A61K36/48 (EP, US) | Expired patent | It claims a medical composition comprising an aqueous solution (prepared in boiling water) of | |
| 2 | C07H3/08 | Expired patent | It claims an enzymatic process for preparing L-rhamnose from plant material such as | |
| 3 | C07K16/40, C12N15/29, C12N15/82, C12N9/04, (IPC1-7): A01H1/00, C12N15/29, C12N15/53, C12N15/61, C12N9/02, C12N9/90 | Lapsed | It claims isolated nucleic acid molecules that encode leucoanthocyanidin reductases of plants such as | |
| 4 | C07K14/415, C12N15/29, C12N15/82, (IPC1-7): C12N15/29, C12N15/82, C12P19/04, C12P21/02 | Expired patent | It claims an isolated plant gum polynucleotide or synthetic genes that help to improve gum Arabic production in plants ( | |
| 5 | A61L27/00, C08B11/12, C08B11/20, C08B37/00, C08B37/06, C08F2/46, C08G63/00, C08H1/06, C08H6/00, C08H7/00, C08J3/28 (IPC1-7): C08F2/46, C08G63/00, C08H5/02 | Expired patents | ||
| 6 | ||||
| 7 | A23L1/308, A23L29/20, A61K31/736, A61P1/14, A61P3/06, A61P3/10, A61P35/00, C08B37/00 | Lapsed | It claims a water-soluble modified gum Arabic that has a total dietary fiber content of 90% or more, which was prepared by heating gum Arabic ( | |
| 8 | C07H1/08, C13K13/00, (IPC1-7): C13K13/00 | Lapsed | It claims a process of recovering arabinose from vegetable fiber (exudate gum such as gum Arabic, gum ghatti, and gum tragacanth) [ | |
| 9 | A61K9/006 (EP), A61K9/127 (EP), A61K9/7007 (EP) | No national phase entry | It claims a solid composition for intra-oral/buccal delivery of insulin encompassing insulin, a hydrophilic polymer (such as gum Talha or | |
| 10 | A23L27/00, A23L27/30, A23L1/305, A23L2/52, A23L2/60, A61K31/575 | Patented case | It claims a sweetener composition comprising rebaudioside A (purity > 97%), erythritol, and a sweet taste improving polymer (such as gum | |
| 11 | A23L27/00, A23L27/30 | Abandoned in 2011 | It claims a synthetic sweetener composition with an improved taste profile comprising a sweet taste improving polymer ( | |
| 12 | A61K35/00, A61K36/48 | Lapsed | It claims the use of gum Arabic ( | |
| 13 | C02F1/58, C08B37/00 | Patented case | It claims a tannin-free talha gum ( | |
| 14 | A61K36/48, A61P19/10 | Lapsed | It claims the use of gum Arabic ( | |
| 15 | A23L1/275, A23L17/00 | Withdrawn | It claims a method for uniformly coloring fish meat (salmon meat) utilizing a 10% aqueous solution of | |
| 16 | A61C19/06, A61C5/14, A61J17/00 | Abandoned in 2014 | It claims an oral device to dispense substances in an oral cavity comprising a natural gum (gum Arabic such as | |
| 17 | A21D13/00, A21D2/36 | Withdrawn | It claims a nutritional chayote bread containing gum Arabic ( | |
| 18 | A23L2/39, A23L2/62 | Patented case | It claims a stable and nutritional peanut protein solid beverage comprising gum Arabic ( | |
| 19 | A23G9/32, A23G9/38 | Abandoned in 2018 | It claims a protein-fortified frozen dessert formulation utilizing gum Arabic ( | |
| 20 | A23G3/38, A23G3/54 | Abandoned in 2017 | It claims a confectionary product (chewing gums and candies) comprising a film-forming agent (gum tahla) [ | |
| 21 | A23L33/155, A61K31/07 | Patented case | It claims a composition of dried particles of gum ghatti, gum | |
| 22 | A23L29/25, C08B37/00, C08L5/00, A23L2/52 | Patented case | It claims an improved gum Arabic ( | |
| 23 | A23L29/10, A23L33/10, A61K36/14, A61K47/36, A61K8/73, A61K8/9761, A61P11/10, A61P11/14, A61P9/12, A61Q5/02, A61Q5/12 | Withdrawn | It claims a functional surfactant/emulgent based on | |
| 24 | A61K31/715, A61K31/723, A61K31/733, A61K35/744, A61K35/747, A61K36/48, A61K47/02, A61K47/10, A61K47/12, A61K47/26, A61K47/36, A61K47/38, A61K47/46, A61K8/02, A61K8/24, A61K8/34, A61K8/36, A61K8/60, A61K8/73, A61K8/97, A61K8/99, A61K9/00, A61Q11/00 | Abandoned in 2019 | It claims a dental synbiotic lozenge encompassing adhesive prebiotics (inulin, | |
| 25 | A23L27/00, A23L27/30, A23L33/21 | Under examination | It claims a sugar substitute composition comprising a digestion resistant soluble fiber ( | |
| 26 | A61K36/48, A61K38/02, A61K8/73, A61K8/9789, A61P17/16, A61P43/00, A61Q19/00, C08B37/00 | Under examination | It claims a plant proteoglycan (molecular weight of 900,000-3,500,000; total aldehyde content = 2.0 μmol equivalent/g or less) obtained from | |
| 27 | G01N21/359 | Under examination | It claims a method for determining the mixing/contamination of different types of gum into gum Arabic ( | |
| 28 | A61K31/05, A61K31/4375, A61P3/06 | Entered into national phase | It claims a food supplement comprising a mixture of berberine, resveratrol, and one nutrient with properties of regulating the lipid profile ( | |
| 29 | A61K8/9789, A61Q19/00, C08B37/00, A23L33/105, A61K38/02 | No national phase entry | ||
| 30 | A61K31/05, A61K9/50 | Under examination | It claims a water-dispersible microencapsulated composition containing 10–20% of cannabinoid and at least one gum |